Amy Wulke
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,524 of the $10,876 with a category attached, or 69.2%. 32 manufacturers reported payments, led by Alkermes, Inc. at 36.4% of the total. 2025 is the largest year on record at $4,714, more than ten times the $96 reported in 2021. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $33.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$4K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$808
- GSK$726
- Supernus Pharmaceuticals, Inc.$541
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$500
- plus $3K from 26 others
What the payments were for
- Consulting fees$5605%
- Speaking & faculty fees$2,70025%
- Food & beverage$7,52469%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 23 | $3,955 |
| AbbVie | 46 | $1,089 |
| Otsuka America Pharmaceutical, Inc. | 14 | $808 |
| GSK | 18 | $726 |
| Supernus Pharmaceuticals, Inc. | 57 | $541 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $500 |
| AstraZeneca | 18 | $454 |
| Pfizer | 21 | $377 |
| Indivior Inc. | 16 | $323 |
| Teva Pharmaceuticals USA, Inc. | 7 | $300 |
| Novo Nordisk | 9 | $245 |
| Exact Sciences | 9 | $176 |
| Lundbeck LLC | 8 | $161 |
| Axsome Therapeutics, Inc. | 4 | $157 |
| Lilly USA, LLC | 9 | $149 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $122 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $101 |
| Orexo US, Inc. | 5 | $89 |
| Neurocrine Biosciences, Inc. | 4 | $80 |
| Braeburn Inc. | 4 | $76 |
| Dexcom, Inc. | 3 | $67 |
| Amgen | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| OWP Pharmaceuticals, Inc. | 1 | $21 |
| Corium, LLC | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$3,367
- LYBALVI$499
- REXULTI$464
- VRAYLAR$358
- CAPLYTA$357
- AREXVY$242
- ABILIFY ASIMTUFII$239
- ABILIFY MAINTENA$239
- QELBREE$125
- COBENFY$125
- Wegovy$122
- Auvelity$122
- Austedo XR$107
- AIRSUPRA$105
How this compares
$10,876 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 18 | $17,475 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 74 | $12,143 |
| EliquisApixaban | 13 | $11,658 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,820 |
| FarxigaDapagliflozin Propanediol | 13 | $8,521 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,112 |
| Pregabalin | 13 | $988 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $773 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $579 |
| Gabapentin | 37 | $417 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $356 |
| Atorvastatin Calcium | 38 | $341 |
| Levothyroxine Sodium | 28 | $254 |
| Omeprazole | 17 | $190 |
| Ibuprofen | 20 | $163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $245 | $17,47518 claims |
| PfizerEliquis | $377 | $11,65813 claims |
| GSKTrelegy Ellipta | $726 | $10,82013 claims |
| AstraZenecaFarxiga | $454 | $8,52113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Flint
- Rachael CompeauFlint$62K
- Julie WidzinskiFlint$16K
- Laura SzakalFlint$10K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.